SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
SciClone Pharmaceuticals (Holdings) Ltd
Income from Continuing Operations
SciClone Pharmaceuticals (Holdings) Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
S
|
SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
|
Income from Continuing Operations
¥1.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Income from Continuing Operations
¥3.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥4.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥4.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income from Continuing Operations
-¥780.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is SciClone Pharmaceuticals (Holdings) Ltd's Income from Continuing Operations?
Income from Continuing Operations
1.1B
CNY
Based on the financial report for Dec 31, 2023, SciClone Pharmaceuticals (Holdings) Ltd's Income from Continuing Operations amounts to 1.1B CNY.
What is SciClone Pharmaceuticals (Holdings) Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
16%
Over the last year, the Income from Continuing Operations growth was 31%. The average annual Income from Continuing Operations growth rates for SciClone Pharmaceuticals (Holdings) Ltd have been 14% over the past three years , 16% over the past five years .